Results 11 to 20 of about 1,816,514 (190)

The evolving role of multi-modality imaging in transcatheter tricuspid valve interventions [PDF]

Frontiers in Cardiovascular Medicine, 2022
Tricuspid valve pathophysiology is not well-understood. Emergence of novel transcatheter tricuspid therapies has fueled the requirements for improved imaging visualization techniques and interventional imaging physician skillsets in guiding these complex
Livia Luciana Gheorghe, Romy Hegeman, Martijn Vrijkorte, Nina Wunderlich, Joao Cavalcante, Dee Dee Wang, Bushra Rana, Mani Vannan, Leo Timmers, Martin Swaans   +9 more
doaj   +4 more sources

Echocardiographic guidance in transcatheter tricuspid valve interventions [PDF]

Journal of Cardiovascular Imaging
Abstract Echocardiographic guidance plays a pivotal role in pre-procedural screening and intraprocedural guidance for transcatheter tricuspid valve interventions (TTVI). Pre-procedurally, comprehensive transesophageal echocardiography (TEE) is essential to understand the tricuspid regurgitation (TR) mechanism, quantify TR severity ...
Kevin Ka Ho Kam, Mani Vannan, Alex Pui Wai Lee   +2 more
core   +3 more sources

Time to assess more than prognosis: advancements and challenges in transcatheter tricuspid valve interventions [PDF]

Frontiers in Cardiovascular Medicine
We provide an overview about the current landscape of transcatheter tricuspid valve interventions (TTVI) and summarize recent findings from trials including TRILUMINATE, TRILUMINATE Pivotal, bRIGHT, TRICLASP, TRISCEND, TRISCEND II, TRICUS, and Cardioband
Felix Rudolph, Maria Ivannikova, Tanja K. Rudolph, Volker Rudolph, Muhammed Gerçek, Kai P. Friedrichs   +5 more
doaj   +3 more sources

Rediscovered and Unforgotten: Transcatheter Interventions for the Treatment of Severe Tricuspid Valve Regurgitation [PDF]

US Cardiology Review, 2021
Tricuspid valve regurgitation is both globally prevalent and undertreated. Historically, surgical intervention for isolated tricuspid regurgitation (TR) was avoided despite the prevalence of TR, largely due to poor surgical outcomes and an incomplete ...
Kusha Rahgozar, Sharon Bruoha, Edwin Ho, Ythan Goldberg, Mei Chau, Azeem Latib   +5 more
doaj   +2 more sources

Mitral and Tricuspid Transcatheter Interventions Current Indications and Future Directions [PDF]

Frontiers in Cardiovascular Medicine, 2020
Valvular heart disease is responsible for a high rate of morbidity and mortality, especially in the elderly population. With the emergence of new transcatheter treatment options, the therapeutic spectrum for patients with valvular heart disease has ...
Mirjam Gauri Winkel, Fabien Praz, Peter Wenaweser, Peter Wenaweser   +3 more
doaj   +3 more sources

Transcatheter Tricuspid Valve-In-Ring and Aortic Valve-In-Valve Implantation

The Thoracic & Cardiovascular Surgeon Reports, 2017
Background Transcatheter heart valve (THV) therapies have shown to be an alternative to surgical valve replacement, especially in high-risk patients requiring redo surgery. However, reports of transcatheter-based interventions in tricuspid valve position
Daniel Reichart, Niklas Schofer, Florian Deuschl, Andreas Schaefer, Stefan Blankenberg, Hermann Reichenspurner, Ulrich Schaefer, Lenard Conradi   +7 more
doaj   +2 more sources

Surgical and Transcatheter Tricuspid Valve Interventions: An Electrophysiology-Focused Review [PDF]

Journal of Cardiovascular Development and Disease
Increasing recognition of the clinical impact of isolated tricuspid regurgitation has led to rapid expansion of surgical and transcatheter tricuspid valve interventions.
Kevin S. Tang, Mark W. Abdelnour, Robert M. Tungate, Christina Mansour, Fabio Sagebin, Antonio H. Frangieh, David M. Donaldson   +6 more
doaj   +2 more sources

Screening and Qualification for Transcatheter Tricuspid Valve Interventions—Preliminary Findings from the CAPTURE Pilot Study [PDF]

Life
Background: Transcatheter tricuspid edge-to-edge repair (T-TEER) is the most widely used treatment option for patients with tricuspid regurgitation (TR). In real-world practice, a substantial proportion of referred patients are not eligible for T-TEER or
Adam Rdzanek, Adam Piasecki, Ewa Pędzich, Ewa Ostrowska, Paweł Pawłowicz, Ewa Borowiak, Agnieszka Kapłon-Cieślicka, Janusz Kochman, Mariusz Tomaniak, Piotr Scisło, Francesco Maisano   +10 more
doaj   +2 more sources

Transcatheter treatment for tricuspid valve disease. [PDF]

, 2021
Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid regurgitation (TR). Primary TR results from anatomical abnormality of the tricuspid valve apparatus and is observed in only 8-10% of the patients with tricuspid valve ...
Maisano, Francesco, Praz, F., Kreidel, F., Mangieri, A., Prendergast, B.D., Muraru, Denisa, Hahn, Rebecca T, Zamorano, Jose L, Mangieri, Antonio, Zamorano, J.L., von Bardeleben, Ralph Stephan, Hausleiter, Jörg, Maisano, F., Nickenig, G., Prendergast, Bernard D, Bardeleben, R.S. von, Senni, Michele, Nickenig, Georg, Delgado, V., Praz, Fabien, Lurz, P., Senni, M., Delgado, Victoria, Hausleiter, J., Lurz, Philipp, Hahn, R.T., Kreidel, Felix, Muraru, D.   +27 more
core   +3 more sources

Update on Transcatheter Tricuspid Valve Replacement Therapies

Frontiers in Cardiovascular Medicine, 2021
Severe tricuspid regurgitation is relatively common, especially in the elderly, and portends poor survival. Neither medical therapy nor conventional surgery is efficacious for most patients.
Ythan H. Goldberg, Edwin Ho, Mei Chau, Azeem Latib   +3 more
doaj   +1 more source